Advertisement

Topics

Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug

08:10 EDT 12 Jul 2018 | Xconomy

Just weeks ago, the FDA approved the first ever medicine made from a derivative of marijuana, a drug from GW Pharmaceuticals for a rare form of epilepsy. Yet competition already looms from San Diego’s Zogenix, thanks to new data the Emeryville, CA, company reports this morning. Zogenix (NASDAQ: ZGNX) said that its experimental drug ZX008 […]

Original Article: Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug

NEXT ARTICLE

More From BioPortfolio on "Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...